Credit: Kimberly Boyles/Adobe Stock
Payments made to U.S. doctors suggest an influence campaign by Novo Nordisk to promote its weight-loss drugs Wegovy and Saxenda, an investigative report by Reuters has found. The analysis showed that Novo spent approximately $26 million in payments to physicians in the U.S., with that number certain to be higher if another weight-loss drug, Ozempic, were included.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
